Zeposia

Adult patients w/ relapsing remitting multiple sclerosis w/ active disease as defined by clinical or imaging features to decrease frequency of clinical exacerbations.

Recommended dose: 0.92 mg once daily. Dose escalation regimen: 0.23 mg once daily on days 1-4, 0.46 mg once daily on days 5-7, 0.92 mg once daily on days 8 & thereafter. Mild or moderate chronic hepatic impairment (Child-Pugh class A or B) Complete the 7-day dose escalation regimen & then take 0.92 mg once every other day.

May be taken with or without food.

Hypersensitivity. Immunodeficient state. Patients who in the last 6 mth experienced MI, unstable angina, stroke, transient ischaemic attack, decompensated heart failure requiring hospitalization or NYHA class III/IV heart failure. History or presence of 2nd-degree AV block type II or 3rd-degree AV block or sick sinus syndrome unless patient has functioning pacemaker. Severe active infections, active chronic infections (eg, hepatitis & TB). Active malignancies. Concomitant use w/ MAOIs. Severe hepatic impairment (Child-Pugh class C). Women of childbearing potential not using effective contraception. Pregnancy.

Immunosuppressants

L04AE02 - ozanimod ; Belongs to the class of sphingosine-1-phosphate (S1P) receptor modulators. Used as immunosuppressants.

POM